Lanzhou Foci Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of December 2022: 0.08%

Lanzhou Foci Pharmaceutical Co Ltd (002644) has an Asset Resilience Ratio of 0.08% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002644 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥2.00 Million
≈ $292.89K USD Cash + Short-term Investments

Total Assets

CN¥2.61 Billion
≈ $381.40 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2022)

This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Lanzhou Foci Pharmaceutical Co Ltd (002644) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002644 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.00 Million 0.08%
Total Liquid Assets CN¥2.00 Million 0.08%

Asset Resilience Insights

  • Limited Liquidity: Lanzhou Foci Pharmaceutical Co Ltd maintains only 0.08% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Lanzhou Foci Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Lanzhou Foci Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Lanzhou Foci Pharmaceutical Co Ltd (2015–2022)

The table below shows the annual Asset Resilience Ratio data for Lanzhou Foci Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 0.08% CN¥2.00 Million
≈ $292.89K
CN¥2.59 Billion
≈ $378.50 Million
-1.27pp
2020-12-31 1.34% CN¥32.08 Million
≈ $4.69 Million
CN¥2.39 Billion
≈ $349.32 Million
+1.23pp
2018-12-31 0.11% CN¥2.90 Million
≈ $424.36K
CN¥2.52 Billion
≈ $369.34 Million
-27.87pp
2017-12-31 27.98% CN¥657.50 Million
≈ $96.21 Million
CN¥2.35 Billion
≈ $343.85 Million
-6.04pp
2016-12-31 34.03% CN¥693.00 Million
≈ $101.41 Million
CN¥2.04 Billion
≈ $298.04 Million
+17.73pp
2015-12-31 16.29% CN¥222.00 Million
≈ $32.49 Million
CN¥1.36 Billion
≈ $199.36 Million
--
pp = percentage points

About Lanzhou Foci Pharmaceutical Co Ltd

SHE:002644 China Drug Manufacturers - Specialty & Generic
Market Cap
$547.74 Million
CN¥3.74 Billion CNY
Market Cap Rank
#11902 Global
#3447 in China
Share Price
CN¥7.33
Change (1 day)
-2.40%
52-Week Range
CN¥7.33 - CN¥11.76
All Time High
CN¥18.02
About

LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more